Aastrom Biosciences' CEO to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference
12 May 2006 - 6:50AM
PR Newswire (US)
ANN ARBOR, Mich., May 11 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) today announced that R. Douglas
Armstrong, Ph.D., Chief Executive Officer and Chairman, will
present at the Rodman & Renshaw 3rd Annual Global Healthcare
Conference. The conference will be held May 15 - 16th at the Le
Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Dr. Armstrong
will present at 2:20 a.m. (Eastern Time), or 8:20 a.m. (Monte
Carlo), on Tuesday, May 16th. (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) A live
webcast of Aastrom's presentation can be accessed by logging onto
the web at http://wsw.com/webcast/rrshq8/astm/ . A replay of the
presentation will be archived for 90 days after the conference, at
the same site. For more information about the Rodman & Renshaw
3rd Annual Global Healthcare Conference, please visit Rodman &
Renshaw's website at http://www.rodmanandrenshaw.com/ . About
Aastrom Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM)
is developing products for the repair or regeneration of multiple
human tissues, based on its proprietary Tissue Repair Cell (TRC)
adult stem cell technology. Aastrom's TRC products contain large
numbers of stromal, stem and progenitor cells that are produced
from a small amount of bone marrow cells originating from the
patient. The AastromReplicell(R) System, an industry-unique
automated cell product manufacturing platform, was developed for
the production of standardized, patient-specific TRC products. TRC
products have been used safely in humans as a substitute for bone
marrow stem cells, and are currently in clinical trials for bone
grafting (long bone fractures and spine fusion) and blood vessel
regeneration (diabetic limb ischemia) applications. The Company has
recently reported positive interim clinical trial results for its
TRCs demonstrating both the clinical safety and ability of TRCs to
induce healthy new tissue growth (long bone fractures and jaw bone
reconstruction). Most recently, the Company's proprietary TRCs
received an Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) for use in the treatment of osteonecrosis at
the hip. For more information, visit Aastrom's website at
http://www.aastrom.com/ . This document contains forward-looking
statements, including without limitation, statements regarding
product development objectives, market development plans, and
potential advantages and applications of Tissue Repair Cells, which
involve certain risks and uncertainties. The forward-looking
statements are also identified through use of the words "plans,"
and other words of similar meaning. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; Kevin McGrath of Cameron
Associates, +1-212-245-4577 Web site: http://www.aastrom.com/
http://www.rodmanandrenshaw.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024